182 related articles for article (PubMed ID: 19650780)
1. Plasma soluble tumour necrosis factor-alpha receptor 2 is elevated in obesity: specific contribution of visceral adiposity.
Cartier A; Côté M; Bergeron J; Alméras N; Tremblay A; Lemieux I; Després JP
Clin Endocrinol (Oxf); 2010 Mar; 72(3):349-57. PubMed ID: 19650780
[TBL] [Abstract][Full Text] [Related]
2. Visceral obesity and plasma glucose-insulin homeostasis: contributions of interleukin-6 and tumor necrosis factor-alpha in men.
Cartier A; Lemieux I; Alméras N; Tremblay A; Bergeron J; Després JP
J Clin Endocrinol Metab; 2008 May; 93(5):1931-8. PubMed ID: 18319319
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of soluble tumor necrosis factor-alpha receptor 2 are linked to insulin resistance and glucose intolerance in children.
Gupta A; Ten S; Anhalt H
J Pediatr Endocrinol Metab; 2005 Jan; 18(1):75-82. PubMed ID: 15679072
[TBL] [Abstract][Full Text] [Related]
4. Effect of 3-month L-arginine supplementation on insulin resistance and tumor necrosis factor activity in patients with visceral obesity.
Bogdanski P; Suliburska J; Grabanska K; Musialik K; Cieslewicz A; Skoluda A; Jablecka A
Eur Rev Med Pharmacol Sci; 2012 Jun; 16(6):816-23. PubMed ID: 22913215
[TBL] [Abstract][Full Text] [Related]
5. Plasma levels of soluble tumor necrosis factor-alpha receptors are related to total and LDL-cholesterol in lean, but not in obese subjects.
Straczkowski M; Kowalska I; Nikolajuk A; Adamska A; Karolczuk-Zarachowicz M; Karczewska-Kupczewska M; Kozlowska A; Gorska M
Cardiovasc Diabetol; 2006 Jun; 5():14. PubMed ID: 16803616
[TBL] [Abstract][Full Text] [Related]
6. Age-related differences in inflammatory markers in men: contribution of visceral adiposity.
Cartier A; Côté M; Lemieux I; Pérusse L; Tremblay A; Bouchard C; Després JP
Metabolism; 2009 Oct; 58(10):1452-8. PubMed ID: 19595381
[TBL] [Abstract][Full Text] [Related]
7. Plasma levels of the soluble fraction of tumor necrosis factor receptor 2 and insulin resistance.
Fernández-Real JM; Broch M; Ricart W; Casamitjana R; Gutierrez C; Vendrell J; Richart C
Diabetes; 1998 Nov; 47(11):1757-62. PubMed ID: 9792545
[TBL] [Abstract][Full Text] [Related]
8. Tumor necrosis factor system activity is associated with insulin resistance and dyslipidemia in myotonic dystrophy.
Fernández-Real JM; Molina A; Broch M; Ricart W; Gutiérrez C; Casamitjana R; Vendrell J; Soler J; Gómez-Sáez JM
Diabetes; 1999 May; 48(5):1108-12. PubMed ID: 10331417
[TBL] [Abstract][Full Text] [Related]
9. Smoking, fat mass and activation of the tumor necrosis factor-alpha pathway.
Fernandez-Real JM; Broch M; Vendrell J; Ricart W
Int J Obes Relat Metab Disord; 2003 Dec; 27(12):1552-6. PubMed ID: 12975637
[TBL] [Abstract][Full Text] [Related]
10. Visceral adiposity is closely correlated with neck circumference and represents a significant indicator of insulin resistance in WHO grade III obesity.
Yang L; Samarasinghe YP; Kane P; Amiel SA; Aylwin SJ
Clin Endocrinol (Oxf); 2010 Aug; 73(2):197-200. PubMed ID: 20050862
[TBL] [Abstract][Full Text] [Related]
11. Soluble tumor necrosis factor-alpha receptors in young obese subjects with normal and impaired glucose tolerance.
Dzienis-Straczkowska S; Straczkowski M; Szelachowska M; Stepien A; Kowalska I; Kinalska I
Diabetes Care; 2003 Mar; 26(3):875-80. PubMed ID: 12610052
[TBL] [Abstract][Full Text] [Related]
12. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men.
Côté M; Matias I; Lemieux I; Petrosino S; Alméras N; Després JP; Di Marzo V
Int J Obes (Lond); 2007 Apr; 31(4):692-9. PubMed ID: 17224929
[TBL] [Abstract][Full Text] [Related]
13. Increased visceral adipose tissue mass is associated with increased C-reactive protein in patients with manifest vascular diseases.
Faber DR; van der Graaf Y; Westerink J; Visseren FL
Atherosclerosis; 2010 Sep; 212(1):274-80. PubMed ID: 20494358
[TBL] [Abstract][Full Text] [Related]
14. Body fat changes and activity of tumor necrosis factor α system--a 5-year follow-up study.
Olszanecka-Glinianowicz M; Chudek J; Kocełak P; Szromek A; Zahorska-Markiewicz B
Metabolism; 2011 Apr; 60(4):531-6. PubMed ID: 20580040
[TBL] [Abstract][Full Text] [Related]
15. Visceral and not subcutaneous abdominal adiposity reduction drives the benefits of a 1-year lifestyle modification program.
Borel AL; Nazare JA; Smith J; Alméras N; Tremblay A; Bergeron J; Poirier P; Després JP
Obesity (Silver Spring); 2012 Jun; 20(6):1223-33. PubMed ID: 22262155
[TBL] [Abstract][Full Text] [Related]
16. The fatty acid transporter FAT/CD36 is upregulated in subcutaneous and visceral adipose tissues in human obesity and type 2 diabetes.
Bonen A; Tandon NN; Glatz JF; Luiken JJ; Heigenhauser GJ
Int J Obes (Lond); 2006 Jun; 30(6):877-83. PubMed ID: 16418758
[TBL] [Abstract][Full Text] [Related]
17. Plasma interleukin-8 concentrations are increased in obese subjects and related to fat mass and tumor necrosis factor-alpha system.
Straczkowski M; Dzienis-Straczkowska S; Stêpieñ A; Kowalska I; Szelachowska M; Kinalska I
J Clin Endocrinol Metab; 2002 Oct; 87(10):4602-6. PubMed ID: 12364441
[TBL] [Abstract][Full Text] [Related]
18. Adiponectinemia in visceral obesity: impact on glucose tolerance and plasma lipoprotein and lipid levels in men.
Côté M; Mauriège P; Bergeron J; Alméras N; Tremblay A; Lemieux I; Després JP
J Clin Endocrinol Metab; 2005 Mar; 90(3):1434-9. PubMed ID: 15598678
[TBL] [Abstract][Full Text] [Related]
19. Increased plasma-soluble tumor necrosis factor-alpha receptor 2 level in lean nondiabetic offspring of type 2 diabetic subjects.
Straczkowski M; Kowalska I; Stepien A; Dzienis-Straczkowska S; Szelachowska M; Kinalska I
Diabetes Care; 2002 Oct; 25(10):1824-8. PubMed ID: 12351485
[TBL] [Abstract][Full Text] [Related]
20. Trunk muscle quality assessed by computed tomography: Association with adiposity indices and glucose tolerance in men.
Maltais A; Alméras N; Lemieux I; Tremblay A; Bergeron J; Poirier P; Després JP
Metabolism; 2018 Aug; 85():205-212. PubMed ID: 29656048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
